Excedr Monthly | August, 2024
We're back with the latest edition of Excedr Monthly, a biotech newsletter for founders, scientists, and the broader life sciences community—full of resources to help you navigate the ins and outs of a tough industry. Let's jump into it.
In today's newsletter:
Quick Biotech News Roundup—
A short roundup of noteworthy events in Biotech this month.
Latest from the Biotech Startups Podcast—
Presented by Excedr, a podcast for scientist-entrepreneurs.
This month, we had three guests on the show:
Every guest we have on has a conversation with Jon over a four part series. All four parts of Shekhar and Noam's episodes are live. Parts one and two of Jon's conversation with Doug are available, with parts three and four coming next week!
Find all the latest episodes of The Biotech Startups Podcast here.
领英推荐
Blog Posts—
Editor's Picks from the Excedr Blog.
Companies often fund their operations and asset purchases through a combination of debt and equity financing, which together form the financial structure of the business. This structure includes both short-term and long-term debt and equity, with each type offering distinct advantages and disadvantages. For startup founders, understanding these options is crucial for making informed financing decisions.
When your startup has gathered early data and gained momentum, it may be time to seek angel funding. This early capital can cover initial costs and provide runway for operations. Angel investors can often be more flexible in negotiations than VCs, which might be what you're looking for. However, you might not get access to the same level of additional resources. Nonetheless, securing funding from a reputable angel investor can boost your credibility and open valuable networking opportunities.
As an early-stage life science company founder, raising funds from investors is often necessary to drive growth. However, understanding what investors expect from you and what you should expect from them can be challenging. Clarifying these expectations during and after fundraising can help simplify and strengthen relationships between both parties.
There are various fundraising options biotechs can tap into, from VCs to grants and public funding. While securing a grant can be challenging, it offers valuable benefits such as funding specific projects, building industry relationships, receiving peer feedback, and enhancing credibility. Knowing which grants you are eligible for is the just first step to securing some capital for your startup.
Till next time.
-Tom & the team at Excedr ??????